proLékaře.cz / Topic / Rare Diseases

You can confirm or exclude ATTRv amyloidosis through genetic testing

16. 3. 2022

Confirm the diagnosis of ATTRv
amyloidosis in your patients
with GeneAct™

Hereditary transthyretin amyloidosis (ATTRv or hATTR) is a progressive and potentially fatal multi-organ disease.¹ Given the considerable diversity of symptoms, including neurological and cardiac ones, diagnosing ATTRv amyloidosis can often be challenging.¹

Genetic testing is a crucial part of diagnostic procedures and recommendations. Testing the gene encoding
transthyretin (TTR) should be performed on patients with warning signs or a family history of ATTRv amyloidosis.^1, 6

Due to the rapid progression of the disease, early and accurate diagnosis
is significantly beneficial for patients with ATTRv amyloidosis.^{2, 3, 5, 7, 8}
Genetic testing helps shorten the time to diagnosis and accelerate the initiation of appropriate treatment.²

A new diagnostic service has been launched

A free service easing the diagnosis of ATTRv amyloidosis is now available to you and your patients through a partnership between Alnylam and ARCHIMEDLife.

GeneAct™ is a trademark of Alnylam Pharmaceuticals

GeneAct™ enables the identification of ATTRv amyloidosis in patients over 18 years old who have a family history of the disease or exhibit neurological, orthopedic, cardiac, or other symptoms associated with ATTRv amyloidosis, such as:⁶

• Sensory neuropathy
• Motor neuropathy
• Autonomic nervous system disorders
• Heart disease
• Bilateral carpal tunnel syndrome
• Lumbar spinal canal stenosis
• Renal abnormalities
• Ocular changes
• Atypical chronic inflammatory
demyelinating polyneuropathy (CIDP)
• Atypical motor neuron disease (MND)
• Gait and posture disturbances
• Unexplained weight loss
• Positive imaging/biopsy findings

The GeneAct™ service is supported by Alnylam, so you and your patients can use it for free.

You are about to visit a website that is not under the control of Alnylam Pharmaceuticals. Therefore, Alnylam does not endorse its content and is not responsible for its accuracy or practices/standards it includes. Alnylam Pharmaceuticals is not responsible for the security level of third-party websites. All contained trademarks are the property of their respective owners.

If you suspect ATTRv
amyloidosis, request testing

If you have any questions, send them by email to info@archimedlife.com

Alnylam provides financial support for GeneAct™ testing, but the responsibility for the services remains with ARCHIMEDLife.

References:
1. Maurer MS, et al. for the Amyloidosis Research Consortium. Circ Heart Fail. 2019; 12(9): e006075.
2. Adams D, et al. Nat Rev Neurol. 2019; 15(7): 387–404.
3. Swiecicki PL, et al. Amyloid. 2015; 22(2): 123–131.
4. Sattianayagam PT, et al. Eur Heart J. 2012; 33(9): 1120–1127.
5. González-Duarte A, et al. J Neurol. 2020; 267(3): 703–712.
6. Adams D, et al. J Neurol. 2021; 268(6): 2109–2122.
7. Polydefkis M, et al. Presented at PNS Annual Meeting; 22–26 June 2019; Genoa, Italy.
8. Kristen AV, et al. Neurodegener Dis Manag. 2019; 9(1): 5–23.

For physicians only
Created and financed by Alnylam Pharmaceuticals

NP-CZE-00034 | July 2021

Did you like this article? Would you like to comment on it? Write to us. We are interested in your opinion. We will not publish it, but we will gladly answer you.